Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium
Karlijn de Joode(Erasmus MC Cancer Institute), Susan C. van ‘t Westeinde, Johan A F Koekkoek(Leiden University Medical Center), Karin H. Herbschleb(Radboud University Nijmegen), Astrid A.M. van der Veldt(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Anne‐Marie C. Dingemans(Erasmus MC Cancer Institute), John B.A.G. Haanen(Leiden University Medical Center), Jessica S.W. Borgers(The Netherlands Cancer Institute), Yarne Klaver, Jan C. Drooger, Jan Willem B. de Groot(Isala), Gerben Bootsma(Zuyderland Medisch Centrum), Pim Mutsaers(Erasmus MC Cancer Institute), Cordula Pitz, Brigitte C.M. Haberkorn(Maasstad Ziekenhuis), Hanneke W.M. van Laarhoven(Dutch Cancer Society), D.M. van Diepen, Marissa Cloos(Erasmus MC Cancer Institute), Cor H. van der Leest(Roche (Canada)), Nico G. J. van Diemen(Ziekenhuis Bernhoven), Luc J. A. Strobbe(Canisius-Wilhelmina Ziekenhuis), L.J.C. van Warmerdam, Laurens V. Beerepoot(Elisabeth-TweeSteden Ziekenhuis), Esther Oomen‐de Hoop(Erasmus MC Cancer Institute), Daphne W. Dumoulin(Erasmus MC), A.L. Peerdeman(Ziekenhuis Bernhoven), Paul Hamberg(Sint Franciscus Gasthuis), Otto Visser(Netherlands Comprehensive Cancer Organisation), Marije Slingerland(Leiden University Medical Center), Haiko J. Bloemendal(Meander Medisch Centrum), Veerle J. Nuij, Elisabeth G.E. de Vries(Karolinska University Hospital), Femke S. van der Meer, Hans M. Westgeest(Amphia Ziekenhuis), Erica J. Geraedts(Groene Hart Ziekenhuis), Elisabeth A. Kastelijn(St. Antonius Ziekenhuis), Eduard J. Libourel(Erasmus MC Cancer Institute), Raban Heller(Bundeswehrkrankenhaus), Pepijn Brocken(Zuyderland Medisch Centrum), Frederiek Terheggen, Annemarie Becker‐Commissaris(Amsterdam University Medical Centers), M. Tiemessen(Erasmus MC), Franchette W.P.J. van den Berkmortel(Zuyderland Medisch Centrum), Jolien Tol(Jeroen Bosch Ziekenhuis), J.A. Stigt(Jeroen Bosch Ziekenhuis), Ben E.E.M. van den Borne, Gerarda J.M. Herder, Lizza Hendriks(Maastricht University), L. van Leeuwen(Mount Sinai Hospital), Frank J. Borm
Cited by 9
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
|The Lancet Oncology|2015|2.6k
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
|New England Journal of Medicine|2019|1.4k
Response assessment criteria for brain metastases: proposal from the RANO group
|The Lancet Oncology|2015|1.1k